• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Delta Hepatitis: A Prognostic Study.δ型肝炎患者肝细胞癌风险因素的识别:一项预后研究
J Viral Hepat. 2025 Jun;32(6):e70034. doi: 10.1111/jvh.70034.
2
High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.HBV/HDV 合并感染患者的肝硬化和严重临床事件发生率较高:德国队列的纵向分析。
BMC Gastroenterol. 2020 Jan 30;20(1):24. doi: 10.1186/s12876-020-1168-9.
3
Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis.与乙型肝炎病毒单一感染相比,丁型肝炎病毒双重感染增加了肝细胞癌的风险:一项荟萃分析。
J Chin Med Assoc. 2022 Jan 1;85(1):30-41. doi: 10.1097/JCMA.0000000000000606.
4
Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.慢性丁型肝炎与肝细胞癌:观察性研究的系统评价和荟萃分析。
J Hepatol. 2020 Sep;73(3):533-539. doi: 10.1016/j.jhep.2020.02.030. Epub 2020 Mar 6.
5
Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.冈比亚的丁型肝炎病毒感染、肝硬化和肝细胞癌。
J Viral Hepat. 2019 Jun;26(6):738-749. doi: 10.1111/jvh.13065. Epub 2019 Feb 14.
6
Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.丁型肝炎病毒感染在接受核苷酸/核苷类似物治疗的慢性乙型肝炎患者肝细胞癌发生中的作用。
Sci Rep. 2021 Apr 14;11(1):8184. doi: 10.1038/s41598-021-87679-w.
7
Hepatitis D: A Review.肝炎 D:综述。
JAMA. 2023 Dec 26;330(24):2376-2387. doi: 10.1001/jama.2023.23242.
8
A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa.丁型肝炎病毒在中非肝癌中所起的重要作用已得到证实。
BMC Infect Dis. 2016 Nov 7;16(1):647. doi: 10.1186/s12879-016-1992-2.
9
High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses.蒙古国肝细胞癌的高发病率;与丙型肝炎病毒、乙型肝炎病毒及丁型肝炎病毒的单一感染或合并感染的关联。
J Med Virol. 2006 Dec;78(12):1688-95. doi: 10.1002/jmv.20755.
10
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.接受长期替诺福韦或恩替卡韦治疗的乙型肝炎病毒复制持续的乙型肝炎、肝硬化和丁型肝炎患者的临床结局。
Aliment Pharmacol Ther. 2019 Apr;49(8):1071-1076. doi: 10.1111/apt.15188. Epub 2019 Feb 21.

本文引用的文献

1
Hepatocellular carcinoma: The virus or the liver?肝细胞癌:是病毒还是肝脏?
Liver Int. 2023 Aug;43 Suppl 1:22-30. doi: 10.1111/liv.15253. Epub 2022 Mar 29.
2
Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.丁型肝炎病毒感染在接受核苷酸/核苷类似物治疗的慢性乙型肝炎患者肝细胞癌发生中的作用。
Sci Rep. 2021 Apr 14;11(1):8184. doi: 10.1038/s41598-021-87679-w.
3
Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain.丁型肝炎患者情况的变化:西班牙巴伦西亚地区的单中心经验
World J Hepatol. 2020 Jun 27;12(6):277-287. doi: 10.4254/wjh.v12.i6.277.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.HIV/HBV 共感染患者中与 delta 肝炎相关的死亡率。
J Hepatol. 2017 Feb;66(2):297-303. doi: 10.1016/j.jhep.2016.10.007. Epub 2016 Oct 14.
6
Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors.罗马尼亚的 Delta 肝炎病毒感染:流行率和危险因素。
J Gastrointestin Liver Dis. 2015 Dec;24(4):413-21. doi: 10.15403/jgld.2014.1121.244.dtv.
7
Development and evaluation of a baseline-event-anticipation score for hepatitis delta.丁型肝炎基线事件预测评分的开发与评估
J Viral Hepat. 2014 Nov;21(11):e154-63. doi: 10.1111/jvh.12251. Epub 2014 Mar 27.
8
A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.一项关于丁型肝炎感染病程的28年研究:肝硬化和肝细胞癌的一个风险因素。
Gastroenterology. 2009 May;136(5):1629-38. doi: 10.1053/j.gastro.2009.01.052. Epub 2009 Jan 29.

δ型肝炎患者肝细胞癌风险因素的识别:一项预后研究

Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Delta Hepatitis: A Prognostic Study.

作者信息

Iacob Speranta, Chitul Mirela, Stan Diana, Gheorghe Daria, Grasu Mugur, Iacob Razvan, Gheorghe Cristian, Popescu Irinel, Gheorghe Liliana

机构信息

Fundeni Clinical Institute, Bucharest, Romania.

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

出版信息

J Viral Hepat. 2025 Jun;32(6):e70034. doi: 10.1111/jvh.70034.

DOI:10.1111/jvh.70034
PMID:40358124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12070851/
Abstract

Given that delta hepatitis is associated with a 2-6 times higher risk for hepatocellular carcinoma (HCC) compared to HBV monoinfection, we aimed to identify the negative prognostic factors for complications associated with HDV infection (particularly HCC) and to validate BEA score as a screening tool for HCC in HDV. Our retrospective single centre study included all consecutive admissions of adult patients with chronic HDV infection in the period 01.01.2021-31.12.2022. The negative prognostic factors identified were higher MELD (p < 0.0001) and higher BEA score on admission (p < 0.0001), older age on HBV diagnosis (p < 0.0001) and advanced fibrosis when PegINF was administered (p = 0.01). Good prognostic factors were: Class A-BEA score (p = 0.001), normal platelet count (p = 0.00001), normal albumin level (p = 0.001) and prior treatment with PegInf (p = 0.01). ROC curve showed 78.5% sensitivity for BEA score > 2, validating it as a potential screening tool for HCC. Hence, for patients with BEA score > 2 imaging screening should be intensified in order to early diagnose HCC and prompt access to curative treatment. Additionally, the negative prognostic factors identified (MELD > 15, advanced fibrosis when treated with PegINF or diagnosis with HBV infection at an older age) should encourage more frequent monitoring for HCC compared to local guidelines recommendations.

摘要

鉴于与单纯乙肝病毒感染相比,丁型肝炎患者发生肝细胞癌(HCC)的风险高2至6倍,我们旨在确定丁型肝炎病毒感染相关并发症(尤其是HCC)的不良预后因素,并验证BEA评分作为丁型肝炎病毒感染患者HCC筛查工具的有效性。我们的回顾性单中心研究纳入了2021年1月1日至2022年12月31日期间所有连续入院的慢性丁型肝炎病毒感染成年患者。确定的不良预后因素包括较高的终末期肝病模型(MELD)评分(p<0.0001)、入院时较高的BEA评分(p<0.0001)、乙肝诊断时年龄较大(p<0.0001)以及使用聚乙二醇干扰素(PegINF)治疗时存在重度肝纤维化(p=0.01)。良好的预后因素为:A-BEA评分等级(p=0.001)、血小板计数正常(p=0.00001)、白蛋白水平正常(p=0.001)以及既往接受过PegInf治疗(p=0.01)。受试者工作特征(ROC)曲线显示,BEA评分>2时的敏感度为78.5%,验证了其作为HCC潜在筛查工具的有效性。因此,对于BEA评分>2的患者,应加强影像学筛查,以便早期诊断HCC并及时接受根治性治疗。此外,所确定的不良预后因素(MELD>15、使用PegINF治疗时存在重度肝纤维化或乙肝感染诊断时年龄较大)应促使对HCC的监测频率高于当地指南的建议。